Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altamira Therapeutics (CYTO)
NASDAQ:CYTO
RESEARCH TOOLSreports
Altamira Therapeutics (CYTO) Stock Price & Analysis
576 Followers
CYTO Stock Chart & Stats
Day’s Range$1.35 - $1.65
52-Week Range― - ―
Previous Close$1.44
Volume322.81K
Average Volume (3M)N/A
Market Cap
$3.54M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Aug 15, 2024EPS Estimate
-$2.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Altamira Therapeutics News
Ownership Overview
0.00%
Insiders
0.10% Mutual Funds
0.00% Other Institutional Investors
99.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CYTO FAQ
What was Altamira Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Altamira Therapeutics’s market cap?
Currently, no data Available
When is Altamira Therapeutics’s upcoming earnings report date?
Altamira Therapeutics’s upcoming earnings report date is Aug 15, 2024 which is in 111 days.
How were Altamira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Altamira Therapeutics overvalued?
According to Wall Street analysts Altamira Therapeutics’s price is currently Overvalued.
Does Altamira Therapeutics pay dividends?
Altamira Therapeutics does not currently pay dividends.
What is Altamira Therapeutics’s EPS estimate?
Altamira Therapeutics’s EPS estimate is -$2.34.
How many shares outstanding does Altamira Therapeutics have?
Currently, no data Available
What happened to Altamira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Altamira Therapeutics?
Currently, no hedge funds are holding shares in CYTO
---
Altamira Therapeutics Stock Smart Score
Company Description
Altamira Therapeutics
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
---
Technical Analysis
Avid Bioservices
―
Corcept Therapeutics
―
Crispr Therapeutics AG
―
Crinetics Pharmaceuticals
―
---